Table 3.
Effects of plasma exposure of statins and theirs metabolites on death, re-ischemia events and MACE in patients.
| Characteristics | MACE | Re-ischemia events | Death | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | ||
| Plasma concentration in AT cohort | |||||||
| AT, ng/ml | Q1–Q3 vs Q1 | 0.930 (0.683–1.268) | 0.6472 | 0.861 (0.585–1.266) | 0.4460 | 1.126 (0.655–1.935) | 0.6688 |
| Q3 vs Q1 | 1.166 (0.989–1.375) | 0.0670 | 0.998 (0.801–1.243) | 0.9834 | 1.522 (1.164–1.991) | 0.0022 | |
| Q3 vs Q1–Q3 | 1.455 (1.096–1.931) | 0.0094 | 1.151 (0.777–1.703) | 0.4831 | 2.054 (1.348–3.130) | 0.0008 | |
| 2-AT, ng/ml | Q1–Q3 vs Q1 | 0.995 (0.729–1.360) | 0.9771 | 0.739 (0.505–1.083) | 0.1207 | 1.815 (1.002–3.288) | 0.0492 |
| Q3 vs Q1 | 1.207 (1.022–1.425) | 0.0268 | 1.000 (0.809–1.236) | 1.0000 | 1.765 (1.305–2.386) | 0.0002 | |
| Q3 vs Q1–Q3 | 1.455 (1.097–1.929) | 0.0092 | 1.352 (0.913–2.001) | 0.1323 | 1.705 (1.131–2.570) | 0.0108 | |
| 4-AT, ng/ml | Q1–Q3 vs Q1 | 1.061 (0.763–1.477) | 0.7232 | 0.810 (0.545–1.205) | 0.2984 | 2.498 (1.225–5.094) | 0.0118 |
| Q3 vs Q1 | 1.332 (1.122–1.581) | 0.0011 | 1.094 (0.882–1.357) | 0.4133 | 2.227 (1.559–3.181) | <0.0001 | |
| Q3 vs Q1–Q3 | 1.692 (1.287–2.224) | 0.0002 | 1.477 (1.011–2.158) | 0.0436 | 2.064 (1.386–3.074) | 0.0004 | |
| ATL, ng/ml | Q1–Q3 vs Q1 | 1.161 (0.836–1.612) | 0.3730 | 1.116 (0.744–1.672) | 0.5958 | 1.349 (0.747–2.438) | 0.3209 |
| Q3 vs Q1 | 1.330 (1.119–1.580) | 0.0012 | 1.111 (0.883–1.396) | 0.3695 | 1.806 (1.353–2.411) | <0.0001 | |
| Q3 vs Q1–Q3 | 1.515 (1.151–1.995) | 0.0030 | 1.107 (0.755–1.624) | 0.6029 | 2.406 (1.591–3.636) | <0.0001 | |
| 2-ATL, ng/ml | Q1–Q3 vs Q1 | 1.232 (0.886–1.712) | 0.2141 | 1.091 (0.730–1.630) | 0.6700 | 1.743 (0.940–3.232) | 0.0776 |
| Q3 vs Q1 | 1.338 (1.125–1.593) | 0.0010 | 1.104 (0.879–1.385) | 0.3943 | 1.919 (1.412–2.607) | <0.0001 | |
| Q3 vs Q1–Q3 | 1.451 (1.102–1.910) | 0.0081 | 1.114 (0.759–1.636) | 0.5802 | 2.115 (1.408–3.177) | 0.0003 | |
| 4-ATL, ng/ml | Q1–Q3 vs Q1 | 1.451 (1.014–2.075) | 0.0415 | 1.212 (0.794–1.852) | 0.3728 | 3.072 (1.384–6.817) | 0.0058 |
| Q3 vs Q1 | 1.556 (1.294–1.871) | <0.0001 | 1.254 (0.993–1.582) | 0.0568 | 2.710 (1.827–4.019) | <0.0001 | |
| Q3 vs Q1–Q3 | 1.707 (1.307–2.229) | <0.0001 | 1.299 (0.896–1.884) | 0.1670 | 2.537 (1.708–3.769) | <0.0001 | |
| Plasma concentration in RST cohort | |||||||
| RST, ng/ml | Q1–Q3 vs Q1 | 0.532 (0.347–0.815) | 0.0038 | 0.505 (0.310-0.823) | 0.0061 | 0.684 (0.304–1.540) | 0.3588 |
| Q3 vs Q1 | 0.825 (0.648–1.051) | 0.1191 | 0.728 (0.541–0.978) | 0.0354 | 1.171 (0.780–1.758) | 0.4459 | |
| Q3 vs Q1–Q3 | 1.306 (0.813–2.098) | 0.2701 | 1.073 (0.597–1.927) | 0.8142 | 2.029 (0.967–4.257) | 0.0612 | |
| RSTL, ng/ml | Q1–Q3 vs Q1 | 0.597 (0.381–0.935) | 0.0243 | 0.571 (0.341–0.957) | 0.0333 | 0.693 (0.296–1.622) | 0.3979 |
| Q3 vs Q1 | 1.008 (0.796–1.277) | 0.9448 | 0.934 (0.705–1.237) | 0.6334 | 1.328 (0.882–2.000) | 0.1736 | |
| Q3 vs Q1–Q3 | 1.708 (1.095–2.666) | 0.0184 | 1.523 (0.893–2.598) | 0.1229 | 2.587 (1.244–5.378) | 0.0109 | |
| DM-RST, ng/ml | Q1–Q3 vs Q1 | 0.727 (0.465–1.137) | 0.1620 | 0.781 (0.470–1.299) | 0.3406 | 0.485 (0.202–1.164) | 0.1053 |
| Q3 vs Q1 | 1.019 (0.799–1.299) | 0.8814 | 0.892 (0.660–1.206) | 0.4573 | 1.360 (0.924–2.001) | 0.1194 | |
| Q3 vs Q1–Q3 | 1.474 (0.944–2.301) | 0.0881 | 1.068 (0.615–1.853) | 0.8157 | 3.765 (1.738–8.158) | 0.0008 | |